Literature DB >> 26797702

Structural modeling of p.V31F variant in the aspartoacylase gene.

Navaneethakrishnan Krishnamoorthy1,2, Hatem Zayed3.   

Abstract

Aspartoacylase (ASPA) is an abundant enzyme in the brain, which catalyzes the conversion of N-acetylaspartate into acetate and aspartate, deficiency in its activity leads to degeneration of the white matter of the brain and is a recognized cause of Canavan disease (CD), which affect children. Although genotype-phenotype correlation have been reported for Canavan disease patients, this relationships is still not straightforward. In this communication, we use molecular modeling to address the structural consequences resulting from the missense variant p.V31F in the ASPA enzyme, which we previously reported in a homozygous form in an Egyptian patient with infantile CD. This modeling suggests that this variant brings significant changes to the catalytic core by introducing structural flexibility through neighbouring key residues. In particular, it provides a molecular explanation for the pathogenic effect of this variant and provides a meaningful genotype-phonotype relationships. The mutational impact appears to have an influence on the function of the protein and initiates molecular event for the mechanism of the disease.

Entities:  

Keywords:  Aspartoacylase; Canavan disease; Genotype-phenotype correlation; Molecular dynamics simulation; Mutational modeling; Structure-function relationship

Mesh:

Substances:

Year:  2016        PMID: 26797702     DOI: 10.1007/s11011-016-9796-z

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  17 in total

1.  The Zn-peptidase superfamily: functional convergence after evolutionary divergence.

Authors:  K S Makarova; N V Grishin
Journal:  J Mol Biol       Date:  1999-09-10       Impact factor: 5.469

Review 2.  Canavan disease: an Arab scenario.

Authors:  Hatem Zayed
Journal:  Gene       Date:  2015-02-07       Impact factor: 3.688

3.  Purification and preliminary characterization of brain aspartoacylase.

Authors:  Roger A Moore; Johanne Le Coq; Christopher R Faehnle; Ronald E Viola
Journal:  Arch Biochem Biophys       Date:  2003-05-01       Impact factor: 4.013

Review 4.  Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms.

Authors:  M H Baslow; T R Resnik
Journal:  J Mol Neurosci       Date:  1997-10       Impact factor: 3.444

5.  Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions.

Authors:  M H Baslow; D N Guilfoyle
Journal:  Biochimie       Date:  2012-11-11       Impact factor: 4.079

Review 6.  Canavan disease: a monogenic trait with complex genomic interaction.

Authors:  Sankar Surendran; Kimberlee Michals-Matalon; Michael J Quast; Stephen K Tyring; Jingna Wei; Ed L Ezell; Reuben Matalon
Journal:  Mol Genet Metab       Date:  2003 Sep-Oct       Impact factor: 4.797

7.  Stable isotope dilution analysis of N-acetylaspartic acid in CSF, blood, urine and amniotic fluid: accurate postnatal diagnosis and the potential for prenatal diagnosis of Canavan disease.

Authors:  C Jakobs; H J ten Brink; S A Langelaar; T Zee; F Stellaard; M Macek; K Srsnová; S Srsen; W J Kleijer
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

8.  Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease.

Authors:  R Kaul; G P Gao; K Balamurugan; R Matalon
Journal:  Nat Genet       Date:  1993-10       Impact factor: 38.330

9.  Purification, characterization, and localization of aspartoacylase from bovine brain.

Authors:  R Kaul; J Casanova; A B Johnson; P Tang; R Matalon
Journal:  J Neurochem       Date:  1991-01       Impact factor: 5.372

Review 10.  Canavan disease: biochemical and molecular studies.

Authors:  R Matalon; R Kaul; K Michals
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

View more
  1 in total

1.  Two patients with Canavan disease and structural modeling of a novel mutation.

Authors:  Osama K Zaki; Navaneethakrishnan Krishnamoorthy; Heba S El Abd; Soumaya A Harche; Reem A Mattar; Rana S Al Disi; Mariam Y Nofal; Rajaa El Bekay; Khalid A Ahmed; C George Priya Doss; Hatem Zayed
Journal:  Metab Brain Dis       Date:  2016-08-17       Impact factor: 3.584

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.